



Panacea Biotec

Innovation in support of life



Safe Harbor Statement

- The information, statements and analysis made in this presentation describing company's objectives, projections and estimates are forward looking statements and progressive within the meaning of applicable security laws and regulations.
- The analysis contained here in is based on numerous assumptions. Actual result may vary from those expressed or implied depending upon economic conditions, government policies and other incidental factors.
- No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment.
- This presentation contains information that is confidential, legally privileged or otherwise protected from disclosure.

Contents




- Corporate Overview
- Pharmaceutical Business Overview
- Vaccine Business Overview
- Innovation Capabilities
- Manufacturing Infrastructure
- Contact Information

Corporate Overview

- **Core Business : Pharmaceuticals, Vaccines**
 - 2nd largest vaccine producer in India
 - Leadership position in key pharmaceutical therapeutic segments like Oncology, Nephrology/Transplant, Diabetes, Gastro-intestinals, Health Supplements
- **Key Business Highlights (Pharma)**
 - Commercialized Tacrolimus in US, Europe & ROW countries
 - Commercialized over 25 branded products including PacliAll - Paclitaxel Nanoparticles (albumin Bound) in Emerging Markets & ROW countries
 - 6 ANDAs filed in US and 17 products (ANDA & 505 (b)2 NDA) in pipeline
 - 4 NCEs in development, 1 best in class molecule in phase-1 under US IND
- **Key Business Highlights (Vaccines)**
 - Developed and launched world's first fully liquid pentavalent vaccine and bivalent oral polio vaccine globally
 - Selected by WHO as partner to develop sIPV in collaboration with RIVM, Netherland


Pharmaceuticals Business Overview

- Wholly owned subsidiary in Germany & Switzerland
 - Panacea Biotec Germany GmbH- Focus on specialty hospital products – commercialized Tacrolimus as branded generic (Tacpan) & Mycophenolate
 - Panacea Biotec Switzerland – Focus on Global Business Development , in-licensed products for commercialization in Europe, ANZ
- Strategic Collaborations in North America:
 - Apotex – Co-investment and Marketing Partner for Nanoparticle and Liposome Drug Delivery Products
 - 6 ANDAs being reviewed by USFDA
- Presence in over 20 Emerging markets:
 - CIS, LATAM, Africa, Middle East, Asia
 - 50 branded products
- Strong Presence in Indian Market:
 - 7 Strategic Business Units
 - Leading brands in Diabetes, GI Oncology, Nephrology & Organ Transplant segments



Vaccine Business Overview

- Established presence of over 25 years in vaccines - Leading player in **critical pediatric** vaccines
- Played pivotal role in polio eradication, being the largest supplier of oral polio vaccines to UNICEF and GOI (**supplied over 9 bn doses of oral polio vaccines**)
- Amongst largest suppliers of vaccines to UNICEF, Govt. of India's, National Governments
- Developed and launched **world's first fully liquid pentavalent vaccine** and bivalent oral polio vaccine globally
- Selected amongst first two technology transfer partners for WHO project of Safe & Affordable **sabin IPV (sIPV)** for the developing world in collaboration with RIVM, Netherlands
- **Fully Liquid Hexavalent Vaccine** – Launch Planned – in 2016
- **Pipeline:** Pneumococcal Conjugate Vaccine, Dengue Vaccine



Innovation Capabilities



GRAND : Platform Drug Delivery Systems

- Focus areas : Nanoparticles, Liposomes, Microparticles, Gastroretentive Systems, Oral films
- **Nanoparticle** paclitaxel introduced in India
- 4 high barrier to entry ANDAs filed in US



Sampann : Molecule Specific Drug Delivery Systems, Generics

- Focus areas : Oral modified release, SMEDDS in softgels, Transdermal, MD tablets, High barrier to entry generics
- 10 Novel Drug Delivery products in India
- 2 Products approved in EU, 1 Product approved in US, 1 FTF ANDA under review in US

Onestream : Drug Discovery Novel Biologicals, Biosimilars, Vaccines

- Target identification to development of pre-clinical candidate
- Biosimilars : Darbepoetin, Trastuzumab,
- Vaccines : Pneumococcal, Dengue, Meningococcal, Japanese Encephalitis

Laksh : Drug Discovery Small Molecules

- Target identification to development of pre-clinical candidate
- Focus areas : Metabolic disorders, Anti-infectives, CNS
- 4 NCEs in development



Drug Delivery Technologies

TECHNOLOGY

PRODUCT

- | | |
|--|---|
| <ul style="list-style-type: none"> • Nanoparticle systems: <ul style="list-style-type: none"> – For targeted release and reduced side effect profile – For bioavailability enhancement | <ul style="list-style-type: none"> ➤ Paclitaxel Nanoparticles |
| <ul style="list-style-type: none"> • Liposome systems: <ul style="list-style-type: none"> – For prolongation of circulation time of therapeutic agents – For delivery of vaccines | <ul style="list-style-type: none"> ➤ Doxorubicin Liposomes |
| <ul style="list-style-type: none"> • Microparticle systems: <ul style="list-style-type: none"> – For long acting depot injectables | <ul style="list-style-type: none"> ➤ Leuprolide Depot ➤ Octreotide Depot |
| <ul style="list-style-type: none"> • Advanced oral drug delivery systems <ul style="list-style-type: none"> – Gastroretentive systems (SPORT platform) – Oral films delivery system – Inorganic Particle Synthesis and Delivery | <ul style="list-style-type: none"> ➤ Memantine SPORT ➤ Tadalafil Film ➤ Lanthanum Suspension |
| <ul style="list-style-type: none"> • Inorganic Sol-Gel topical delivery systems | <ul style="list-style-type: none"> ➤ Acyclovir Cream |

Manufacturing facilities (Pharma Formulations)



Source: Management

Location – Baddi, India

- **Start of operations:** April 2006
- **Oncology unit established in 2012**
- **No. of employees:** 425
- **Total built up area-** 70,000 sqm

Capacity

Production Lines	Annual capacity (mns)
Anticancer (Cytotoxic Products)	
Liquid and lyophilized Injectables	1.2
Other Dosage Forms	
Tablets	3,000
Hard Gelatin Caps	650
Soft Gelatin Caps	150
Ointments & Gels	42
Liquid Orals	24

Manufacturing facilities (Pharma Formulations)

- State of art cGMP facility with approvals from global regulatory authorities viz. US FDA, EU agencies, ANVISA, TGA and many other agencies
- 161 products approval received from 14 countries
- Maintain high standards of manufacturing by using state of art GMP compliant machines like Sejong for tablet compression, BQS for packaging
- Equipped for: **Bi-layer tablets, Tablet-in-Tablet, Mini-tablets, Complex Sustained release coatings and Delayed release coatings.**
- Oncology injectable facility is equipped for manufacturing **Conventional, Nano particular, Liposomal, Lyophilized products**

Major Accreditations:

- USFDA
- German Authorities
- Brazil (ANVISA)
- Australia
- Turkey

Manufacturing facilities (Vaccines)

Baddi, HP



Okhla, New Delhi	
Start of operations	1988
Area	50,000 sqft
No. of employees	257
Capacity	820 mn doses p.a. (3 vial filling lines)
Accreditations	Indian NRA WHO GMP*

Baddi, HP

Start of operations	2002
Area	129,167 sqft
No. of employees	253
Capacity	One bn doses p.a. (2 filling lines for bacterial and viral vaccines)
Accreditations	Indian NRA WHO GMP

Lalru, Punjab



Lalru, Punjab

Start of operations	2007
Area	98,000 sqft
No. of employees	473
Capacity	25 mn doses p.a. (recombinant, bacterial, tetanus and cell culture capabilities)
Accreditations	Indian NRA WHO GMP

Two vaccine formulation facilities with a combined capacity of 1 billion doses per annum with capabilities in pre-filled syringes and vials

Indigenous & fully integrated bulk antigen manufacturing facilities

The contents of this Business Profile cannot be copied /shared / printed / distributed / disclosed to any third party without the prior written permission of Panacea Biotec

Thank you

For further Information, please contact:

Rishi Prakash

General Manager - Business Development

Panacea Biotec Ltd ; B-1 Extn. / A-27, Mohan Co-op. Indl. Estate Mathura Road, New Delhi - 110044, India

Direct Phone : +91-11-41578063, Cell: +91-9717772466

Email: rishiprakash@panaceabiotec.com

www.panaceabiotec.com